Clinical Trial of L. Reuteri in Infantile Colic 2017

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

244 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RCT to evaluate the safety and efficacy of Lactobacillus reuteri DSM 17938 to significantly reduce the duration of crying time and fussines in infants from 15days to 4 months of age with colic, feed with human milk (30% sample) or infant formula (70%)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic

NCT01541046

Colic

COMPLETED PHASE2

Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic

NCT01887444

Infantile Colic

WITHDRAWN NA

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

NCT07190859

Infantile Colic

RECRUITING NA

Prevention of Colic With the Probiotic Lactobacillus Reuteri

NCT02577133

Colic

UNKNOWN PHASE2/PHASE3

Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic

NCT00893711

Infantile Colic

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RCT to evaluate the safety and efficacy of Lactobacillus reuteri DSM 17938 administrated for 21 days to significantly reduce the duration of crying time and fussines in infants from 15days to 4 months of age with colic. 66 infants feed with human milk and 180 infant feed with infant formula will be included. As primary outcome we will measure the difference between children receiving L. reuteri DSM 17938, 108 CFU vs children receiving placebo regarding average daily crying duration (minutes per day, from average of crying from days 19 to 21 after randomization), measured by Barr diary. Secondary/exploratory outcomes will be average of crying time on day 7 and 14 (Barr diary) of L. reuteri groups vs placebo group; average of crying and fussing time on day 7, 14 and average from days 19 to 21 after randomization (Barr diary) of L. reuteri groups vs placebo group; responders percentage on day 7, 14 and 21, decrease in daily average crying time of 50% during the study; QoL (PedsQL-2.0-Family Impact Module AU2.0 spa-MX) changes from baseline to days 7, 14 and 21 and Edinburg postnatal depression scale for mothers from baseline to days 7, 14 and 21

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infantile Colic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial, double blind allocation concealment

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Children allocated on different arms will receive drops of probiotics or placebo. Both product are identical in appearence and flavor

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HMilkProb

L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties

Group Type EXPERIMENTAL

L. reuteri DSM 17938 in drops

Intervention Type DIETARY_SUPPLEMENT

L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle

HMilkPlacebo

The placebo consists of an identical formulation except that the L. reuteri is not present

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The placebo consists of an identical formulation except that the L. reuteri is not present

IFormProb

L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties

Group Type EXPERIMENTAL

L. reuteri DSM 17938 in drops

Intervention Type DIETARY_SUPPLEMENT

L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle

IFormPlacebo

The placebo consists of an identical formulation except that the L. reuteri is not present

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The placebo consists of an identical formulation except that the L. reuteri is not present

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L. reuteri DSM 17938 in drops

L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle

Intervention Type DIETARY_SUPPLEMENT

Placebo

The placebo consists of an identical formulation except that the L. reuteri is not present

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Younger than 10 weeks of age
* Full term infant (37-42 weeks gestational age)
* Birth weight ≥ 2,500g
* Apgar score ≥ 7 at 5 minutes
* Infantile colic diagnosed according to modified Wessel's criteria (crying more than 180 min/day during 3 days for at least a week prior to enrolment)
* Parental motivation to postpone changes in the infant feeding mode, unless necessary
* Stated availability throughout the study period
* Parent(s) willingness and ability to fill out charts and questionnaires
* Signed informed consent

Exclusion Criteria

* Failure to thrive
* Chronic illness or major medical problem
* Gastrointestinal disease
* Use of any antibiotic 2 weeks before Day 1 in the study. This applies also to lactating mothers whose infants participate in the trial
* Use of supplements/eaten foods that contain Lactobacillus reuteri, 2 weeks before Day 1
* Use of proton pump inhibitors in the week (7 days) prior to enrolment
* If breastfeeding, use of probiotic by the mother in the week (7 days) prior to enrolment and throughout the study period
* Use of infant formula with hydrolysed protein
* Infant receiving solid foods (such as cereals, mashed fruits or vegetable purée)
* Change of feeding mode planned by parents during the study period

Minimum Eligible Age

1 Week

Maximum Eligible Age

9 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No